Full information on isolate OX9931436 (id:4201)

Projects

This isolate is a member of the following project:

UKMenCar1
United Kingdom Meningococcal Carriage Study - 1999

Provenance/primary metadata

id
4201
isolate
OX9931436
strain designation
B: P1.7-2,4: F1-5: ST-482 (cc41/44)
country
UK [England]
continent
Europe
region
South East
year
1999
age yr
17
age range
15-24
sex
male
disease
carrier
source
throat swab
epidemiology
carrier
species
Neisseria meningitidis
serogroup
B
genogroup
B
capsule group
B
serotype
4
comments
Study Centre: Oxford

Tracking

sender
Ana-Belen Ibarz-Pavon, Centre de Recerca en Salut Internacional de Barcelona (CRESIB) & Centro de Investigacao em Saude da Manhica (CISM)
curator
Auto Tagger
update history
122 updates show details
date entered
2003-12-17
datestamp
2022-04-16

Secondary metadata

Deduced vaccine reactivity

Bexsero reactivity
exact match 
notes
Bexsero notes
NHBA_peptide: 2 is exact match to vaccine variant - peptide sequence match (PMID:27521232);
PorA_VR2: 4 is exact match to vaccine variant - peptide sequence match (PMID:27521232)
Trumenba reactivity
cross-reactive 
notes
Trumenba notes
fHbp_peptide: 4 is cross-reactive to vaccine variant - data derived from MEASURE assays (PMID:29535195), and SBA assays (PMID:27846061, PMID:29236639)

Risk factors

UK school year
12
persons in household
4
antibiotic use
no
cigarettes per day
1-5
passive smoking
no
pubs clubs per week
4-5
persons kissed past week
1

Bexsero® (4CMenB) is a multicomponent vaccine.

  • Protein-based meningococcal vaccines contain surface proteins as vaccine antigens, these proteins demonstrate nucleotide and amino acid sequence diversity.
  • Peptide sequence diversity can be analysed using the Bexsero Antigen Sequence Typing (BAST) scheme1.
  • Bexsero® contains: fHbp peptide 1; NHBA peptide 2; NadA peptide 8; PorA VR2 4.

The Deduced Vaccine Antigen Reactivity (MenDeVAR) Index was developed to combine multiple, complex data that inform the reactivity of each vaccine against specific antigenic variants.

The MenDeVAR Index:

  • isolate contains ≥1 exact sequence match to antigenic variants found in the vaccine.
  • isolate contains ≥1 antigenic variant deemed cross-reactive to vaccine variants through experimental studies.
  • all the isolate's antigenic variants have been deemed not cross-reactive to vaccine variants through experimental studies.
  • isolate contains antigens for which there is insufficient data from or are yet to be tested in experimental studies.

It is important to understand the caveats to interpreting the MenDeVAR Index:

Source of data - These data combine multiple sources of information including: peptide sequence identity through whole genome sequencing; experimental assays developed as indirect measures of the breadth of vaccine protection against diverse meningococci; and assays developed to assess immunogenicity. The Meningococcal Antigen Typing System (MATS)2 assay was used for Bexsero®.

Cross-reactivity definition - An antigenic variant was considered cross-reactive if it had been tested in ≥5 isolates/subjects and was above the accepted threshold in ≥75% of those isolates. This was established through combined analysis of published experimental studies (PMID provided for each variant), not from genomic data. These assays were based on serogroup B disease isolates.

Protein expression - We have not inferred from genomic data, therefore there may be isolates that possess genes but do no express the protein in vivo.

Age of vaccinees - For MATS assay development2, Bexsero® vaccine recipients were infants who had received 3 doses of vaccine and then a booster at 12 months. The pooled sera used for the MATS assay were taken from the toddlers at 13 months of age.

  1. Brehony C, Rodrigues CMC, Borrow R, et al. Distribution of Bexsero® Antigen Sequence Types (BASTs) in invasive meningococcal disease isolates: Implications for immunisation. Vaccine 2016 34(39):4690-7
  2. Donnelly J, Medini D, Boccadifuoco G, et al. Qualitative and quantitative assessment of meningococcal antigens to evaluate the potential strain coverage of protein-based vaccines. Proc Natl Acad Sci USA 2010;107(45):19490-19495

MenDeVAR is described in Rodrigues et al. 2020, J Clin Microbiol 59(1):e02161-20. Please contact us if you have queries.

Click to close

Trumenba® (rLP2086) is a bivalent fHbp-containing vaccine.

  • Protein-based meningococcal vaccines contain surface proteins as vaccine antigens, these proteins demonstrate nucleotide and amino acid sequence diversity.
  • Peptide sequence diversity can be analysed using the fhbp peptide locus.
  • Trumenba® vaccine contains fHbp peptides 45 and 551.

The Deduced Vaccine Antigen Reactivity (MenDeVAR) Index was developed to combine multiple, complex data that inform the reactivity of each vaccine against specific antigenic variants.

The MenDeVAR Index:

  • isolate contains ≥1 exact sequence match to antigenic variants found in the vaccine.
  • isolate contains ≥1 antigenic variant deemed cross-reactive to vaccine variants through experimental studies.
  • all the isolate's antigenic variants have been deemed not cross-reactive to vaccine variants through experimental studies.
  • isolate contains antigens for which there is insufficient data from or are yet to be tested in experimental studies.

It is important to understand the caveats to interpreting the MenDeVAR Index:

Source of data - These data combine multiple sources of information including: peptide sequence identity through whole genome sequencing; experimental assays developed as indirect measures of the breadth of vaccine protection against diverse meningococci; and assays developed to assess immunogenicity. The meningococcal antigen surface expression (MEASURE)2 and serum bactericidal activity (SBA) assays were used for Trumenba®.

Cross-reactivity definition - An antigenic variant was considered cross-reactive if it had been tested in ≥5 isolates/subjects and was above the accepted threshold in ≥75% of those isolates. This was established through combined analysis of published experimental studies (PMID provided for each variant), not from genomic data. These assays were based on serogroup B disease isolates.

Age of vaccinees - The age of vaccine recipients in the experimental studies varies widely, ranging from toddlers to adults, and needs to be taken into consideration when interpreting results. Vaccine studies used different schedules and doses of vaccines.

  1. Jiang HQ, Hoiseth SK, Harris SL, et al. Broad vaccine coverage predicted for a bivalent recombinant factor H binding protein based vaccine to prevent serogroup B meningococcal disease. Vaccine 2010;28(37):6086-93
  2. McNeil LK, Donald RGK, Gribenko A, et al. Predicting the Susceptibility of Meningococcal Serogroup B Isolates to Bactericidal Antibodies Elicited by Bivalent rLP2086, a Novel Prophylactic Vaccine. mBio 2018;9(2):e00036-18

MenDeVAR is described in Rodrigues et al. 2020, J Clin Microbiol 59(1):e02161-20. Please contact us if you have queries.

Click to close

Publications (2)

  • Earle SG, Lobanovska M, Lavender H, Tang C, Exley RM, Ramos-Sevillano E, Browning DF, Kostiou V, Harrison OB, Bratcher HB, Varani G, Tang CM, Wilson DJ, Maiden MCJ (2021). Genome-wide association studies reveal the role of polymorphisms affecting factor H binding protein expression in host invasion by Neisseria meningitidis. PLoS Pathog 17:e1009992
  • Spinsanti M, Brignoli T, Bodini M, Fontana LE, De Chiara M, Biolchi A, Muzzi A, Scarlato V, Delany I (2021). Deconvolution of intergenic polymorphisms determining high expression of Factor H binding protein in meningococcus and their association with invasive disease. PLoS Pathog 17:e1009461

Sequence bin

contigs
237
total length
2,184,554 bp
max length
93,071 bp
mean length
9,218 bp
N50
33,914
L50
20
N90
6,988
L90
72
N95
3,372
L95
94
%GC
51.46
Ns
0
gaps
0
loci tagged
2,218

Show sequence bin

Annotation quality metrics

SchemeScheme lociDesignated lociAnnotation
ScoreStatus
rplF species11100
Finetyping antigens33100
Bexsero Antigen Sequence Typing (BAST)55100
MLST77100
Ribosomal MLST5353100
N. meningitidis cgMLST v21422141099

Analysis

rMLST species identification

RankTaxonTaxonomySupportMatches
SPECIES Neisseria meningitidis Proteobacteria > Betaproteobacteria > Neisseriales > Neisseriaceae > Neisseria > Neisseria meningitidis 100%

Analysis performed: 2022-11-29

Similar isolates (determined by classification schemes)

Some groups only contain this isolate. Show single groups

Experimental schemes are subject to change and are not a stable part of the nomenclature.

Classification schemeUnderlying schemeClustering methodMismatch thresholdStatusGroup
Bact_rmlstc_5Ribosomal MLSTSingle-linkage5experimental698 (3606 isolates)
Bact_rmlstc_4Ribosomal MLSTSingle-linkage4experimental799 (3071 isolates)
Bact_rmlstc_3Ribosomal MLSTSingle-linkage3experimental921 (2747 isolates)
Bact_rmlstc_2Ribosomal MLSTSingle-linkage2experimental1173 (1610 isolates)
Bact_rmlstc_1Ribosomal MLSTSingle-linkage1experimental1665 (1202 isolates)
Nm_cgc_200N. meningitidis cgMLST v2Single-linkage200experimental33 (1708 isolates)
Bact_rmlstc_5Ribosomal MLSTSingle-linkage5experimental698 (3606 isolates)
Bact_rmlstc_4Ribosomal MLSTSingle-linkage4experimental799 (3071 isolates)
Bact_rmlstc_3Ribosomal MLSTSingle-linkage3experimental921 (2747 isolates)
Bact_rmlstc_2Ribosomal MLSTSingle-linkage2experimental1173 (1610 isolates)
Bact_rmlstc_1Ribosomal MLSTSingle-linkage1experimental1665 (1202 isolates)
Nm_cgc_200N. meningitidis cgMLST v2Single-linkage200experimental33 (1708 isolates)
Nm_cgc_100N. meningitidis cgMLST v2Single-linkage100experimental262 (1 isolate)
Nm_cgc_50N. meningitidis cgMLST v2Single-linkage50experimental295 (1 isolate)
Nm_cgc_25N. meningitidis cgMLST v2Single-linkage25experimental307 (1 isolate)
Nm_cgc_10N. meningitidis cgMLST v2Single-linkage10experimental323 (1 isolate)

Schemes and loci

Navigate and select schemes within tree to display allele designations

Tools

Export:
Analysis: